Novartis Delivers 250 millionth Of Coartem Treatment

Novartis has delivered the 250 millionth treatment of Coartem, an artemisinin-based combination therapy (ACT) for the treatment of malaria. The 250,000,000th treatment was delivered to healthcare clinic in Dar es Salaam, Tanzania, said Novartis.

Dr. Daniel Vasella, Chairman and CEO of Novartis, said: With 250 million treatments provided and an estimated 630,000 lives saved, the Novartis Malaria Initiative is the industry’s largest access-to-medicines program in the developing world.

However, malaria demands a collaborative approach. Joining United Against Malaria in its campaign is a promising way to relieve unnecessary suffering due to malaria, he added.

Novartis is said to be the first healthcare company to join United Against Malaria (UAM), a consortium that strives to raise awareness of malaria and achieve the shared goal of ending malaria deaths in Africa by 2015.

Coartem is a three-day malaria treatment and is approved for use in over 80 countries worldwide.